Medicare's new obesity drug coverage starts in July, but the agency hasn't disclosed the cost to taxpayers, who will bear most of the expense for Wegovy and Zepbound prescriptions.
Medicare has announced that adults 65 and older will be able to access Wegovy and Zepbound, two popular weight loss medications, starting in July for a monthly cost of $50. However, the agency has not provided any information on the overall cost of this new coverage to taxpayers, who will be responsible for the majority of the expense. This lack of transparency has significant implications for both the public and Medicare beneficiaries, as the temporary coverage of obesity medications is expected to have a substantial impact on the healthcare system.
The "GLP-1 Bridge" program, which begins on July 1 and runs through December 31, 2027, will provide coverage for millions of new patients and generate billions of dollars in revenue for the manufacturers of these drugs, Eli Lilly and Novo Nordisk. The program's cost is likely to be substantial, given the high demand for these medications and the significant potential benefits they offer for patients struggling with obesity. Despite the importance of this issue, Medicare has not provided any details on the estimated cost of the program or how it will be funded.
The decision to cover these medications through the "GLP-1 Bridge" program is a significant departure from the original plan, which was to test coverage through Medicare Advantage and prescription drug plans. However, the health insurers that run these plans expressed concerns about the high potential costs, leading Medicare to opt for a different approach. As a result, the cost of covering these medications will be borne solely by taxpayers and the beneficiaries who fill prescriptions, rather than being shared with private insurers.
The rollout of the "GLP-1 Bridge" program has significant implications for the healthcare system, and the lack of transparency around its cost is a concern for many stakeholders. As the program gets underway, it will be important to monitor its impact and ensure that it is providing effective and sustainable coverage for patients in need. The fact that Medicare is withholding information on the cost of the program raises questions about the agency's approach to managing its finances and making decisions about coverage. As the program moves forward, it will be essential to have a clear understanding of its costs and benefits to ensure that it is meeting the needs of patients and taxpayers alike.
